Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells $125,565.60 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $22.60, for a total value of $125,565.60. Following the transaction, the vice president directly owned 18,900 shares in the company, valued at $427,140. This trade represents a 22.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David Foehr also recently made the following trade(s):

• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Stock Up 1.1%

Shares of CeriBell stock opened at $23.33 on Friday. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a market cap of $865.54 million, a P/E ratio of -15.45 and a beta of 1.02. The company’s fifty day simple moving average is $18.02 and its two-hundred day simple moving average is $15.11.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. Research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Analysts Set New Price Targets

CBLL has been the subject of a number of research analyst reports. Canaccord Genuity Group raised their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. lowered their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, TD Cowen dropped their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Trading of CeriBell

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after acquiring an additional 1,256 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the 3rd quarter worth approximately $33,000. Police & Firemen s Retirement System of New Jersey lifted its position in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after acquiring an additional 3,502 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in CeriBell during the 4th quarter valued at $145,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.